April 7, 2021
A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3’-Deoxy-3’-18F Fluorothymidine (18F-FLT) Imaging
TYPE OF SARCOMA: Ewing Sarcoma
DRUG: Trabectedin and Irinotecan
ACCRUAL STATUS: Recruiting
OVERALL STUDY PRINCIPAL INVESTIGATOR:
Patrick Grohar, MD, PhD
Associate Professor / Director of Translational Research
Center for Childhood Cancer Research
Children’s Hospital of Philadelphia
CLINICALTRIALS.GOV IDENTIFIER: NCT04067115
FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV
To learn more about this study or to contact the study research staff: